Shares of Novo Nordisk plunged 15% on Monday after the company announced that its next-generation obesity drug failed to meet a key trial objective against a rival treatment from Eli Lilly.
Novo Nordisk said on Monday that its next-generation obesity treatment CagriSema proved less effective than tirzepatide, developed by Eli Lilly, in a head-to-head clinical trial — marking a setback in the competitive race for dominance in the fast-growing weight-loss drug market.
23 Feb 2026-15:15
23 Feb 2026-14:22
